Disitamab Vedotin Plus Tislelizumab in Non–Muscle-Invasive Bladder Cancer

Дата публикации: 08-10-2026 00:00:00

This nonrandomized clinical trial examines the efficacy of disitamab vedotin plus tislelizumab for transurethrally unresectable, ERBB2-positive, very high-risk, non–muscle-invasive bladder cancer in adults who were ineligible for or declined radical cystectomy.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	New treatment approach improves survival, reduces recurrence risk in muscle-invasive bladder cancer	0	11.13	24-07-2026
2	FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer	5	5	08-07-2026
3	Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer	0	8.64	01-08-2026
4	Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer	0	10	28-07-2026
5	New Combination Therapy Shows Promise for Advanced Bladder Cancer	0	11.16	06-08-2026
6	Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer	0	5	18-06-2026
7	Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer	0	14.28	01-01-2025
8	Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer	0	18.85	30-07-2026
9	Checkpoint Inhibitors Plus Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors	0	4.57	01-09-2023

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 13.81. Источник: jamanetwork.com.